EMA Committee Recommends Approval for Pancreatic Cancer Drug Rasonque

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Revolution Medicines' Rasonque (daraxonrasib). This drug is proposed as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma who have previously received at least one systemic therapy. This recommendation follows an expedited, phased review under the EMA's Cancer Medicines Pathfinder project.